Business Wire
19 Nov 2026, 11:45 UTC · 7h ago
Merck and Isomorphic Labs Enter Strategic Research Collaboration
Impact · against what's priced in
The collaboration with Isomorphic Labs is a marginal positive for Merck, as it introduces a new AI-driven pipeline efficiency not currently modeled in the price. However, it does not meaningfully address the core valuation crux regarding Keytruda's patent cliff or the 12.2% CAGR required by the reverse DCF.
- MRK+0.10
Not in the price yet
- In context
The partnership to discover small molecule oncology candidates using AI is a new research initiative; it is distinct from the mRNA vaccine pipeline that the market is currently weighing.
What MRK's price assumes · Sep 11





